

Format for Manuscript Submission: Systematic Reviews

Name of Journal: *World Journal of Gastroenterology*

Manuscript Type: SYSTEMATIC REVIEWS

**Association between orofacial granulomatosis and Crohn's disease in children:
Systematic review**

Lazzerini M *et al.* Orofacial granulomatosis and CD

Marzia Lazzerini, Matteo Bramuzzo, Alessandro Ventura

Marzia Lazzerini, Matteo Bramuzzo, Alessandro Ventura, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, 34137 Trieste, Italy

Matteo Bramuzzo, Alessandro Ventura, University of Trieste, 34137 Trieste, Italy

ORCID number: Marzia Lazzerini (); Matteo Bramuzzo (); Alessandro Ventura ().

Author contributions: Lazzerini M, Bramuzzo M and Ventura A contributed equally to the work; Lazzerini M conceptualized and designed the review together with Ventura A; Lazzerini M and Bramuzzo M carried out the analysis; Lazzerini M drafted the initial manuscript; all authors reviewed and approved the final manuscript as submitted.

Supported by

Conflict-of-interest statement:

PRISMA 2009 Checklist statement:

Corresponding author: Marzia Lazzerini, PhD, Institute for Maternal and Child Health,
IRCCS Burlo Garofolo, via dell'Istria 65/1, 34137 Trieste, Italy.
marzia.lazzerini@burlo.trieste.it

Telephone: +39-40-3785555

Fax: +39-40-3785260

Abstract

BACKGROUND

AIM

To review pediatric cases of orofacial granulomatosis (OFG), report disease characteristics, and explore the association between OFG and Crohn's disease.

METHODS

We conducted a systematic review according to the PRISMA guidelines. We searched Medline, LILACS, Virtual Health Library, and Web of Knowledge in September 2013 for cases of OFG in the pediatric age range (< 18 years), with no language limitations. All relevant articles were accessed in full text. The manual search included references of retrieved articles. We extracted data on patients' characteristics, disease characteristics, association with other diseases, and treatment. We analyzed the data and reported the results in tables and text.

RESULTS

We retrieved 173 reports of OFG in children. Mean age at onset was 11.1 ± 3.8 years (range: 2.0–18 years). Prevalence in males was significantly higher than in females ($P < 0.001$), with a male: female ratio of 2:1. Gastrointestinal signs or symptoms were present in 26.0% of children at the time of OFG diagnosis. Overall, 70/173 (40.4%) children received a concomitant diagnosis of Crohn's disease. In about half (51.4%) of the cases the onset of OFG anticipated the diagnosis of Crohn's disease, with a mean time between the two diagnoses of 13.1 ± 11.6 mo (range: 3–36 mo). Overall, 21/173 (12.1%) of the children with OFG had perianal disease, while 11/173 (6.4%) had a family history of Crohn's disease. Both perianal disease and a family history of Crohn's disease were significantly associated with a higher risk of Crohn's disease diagnosis in children with OFG (RR = 3.10, 95%CI: 2.46–3.90; RR = 2.74, 95%CI: 2.24–3.36, $P < 0.0001$ for both). Treatment of OFG included steroids (70.8% of children) and other immunosuppressive drugs (42.7%), such as azathioprine, thalidomide and infliximab.

CONCLUSION

High prevalence of Crohn's disease in children with OFG suggests that OFG may be a subtype of Crohn's disease.

Key words: Orofacial granulomatosis; Melkersson-Rosenthal syndrome; cheilitis granulomatosa; Crohn's disease; Children

Core tip:

Lazzerini M, Bramuzzo M, Ventura A. Association between orofacial granulomatosis and Crohn's disease in children: A systematic review.

INTRODUCTION

The term orofacial granulomatosis (OFG) is conventionally used to describe patients with granulomatous lesions affecting the orofacial tissues^[1,2]. The disease is uncommon but is increasingly being recognized. Lip swelling and facial swelling are the most common clinical signs of OFG, often presenting with a spectrum of other features (Figure 1)^[3,4]. Over time the majority of patients tend to develop additional lesions, and the lip or facial swelling can become indurated, permanent, and significantly debilitating^[1-4].

The pathogenesis of OFG is still uncertain. Different theories suggested a possible role for allergy, infections, and genetic predisposition^[1,2].

More recently, it has been hypothesized that OFG may be a subtype of Crohn's disease. This hypothesis is based on the following data: (1) histologically OFG is characterized by noncaseating epithelioid cell granulomas that are indistinguishable from the features of Crohn's disease^[1,2]; (2) concurrent intestinal Crohn's disease has been described in 20%–50% of adult patients with OFG^[5,6]; and (3) both OFG and Crohn's disease have a similar clinical course, that is, long-term with a series of recurrent attacks^[1-4].

To the best of our knowledge, no systematic review of pediatric cases of OFG has previously been published. The objective of this work was to systematically review pediatric cases of OFG, and evaluate the association between OFG and Crohn's disease.

MATERIALS AND METHODS

This systematic review was conducted according to the PRISMA guidelines^[6]. We searched Medline, LILACS, Virtual Health Library, and Web of Knowledge in September 2013 for cases of OFG in the pediatric age range (< 18 years), with no language limitations. The search strategy is reported in Table 1. All relevant articles were accessed in full text. The manual search included references of retrieved articles. We extracted data on patients' characteristics, disease characteristics, association with other diseases, and treatment. We analyzed the data and reported the results in the tables and text. Cases of granulomatous perioral dermatitis, Melkersson–Rosenthal syndrome (*i.e.*, cases characterized by facial nerve palsy), and OFG-like lesions after organ transplant

were excluded from this review.

Statistical analysis

RESULTS

The process of study selection is reported in Figure 2. We retrieved 18 case series^[7-23] and 35 case reports^[24-56], for a total of 173 children with OFG. One article could not be found in full text^[57].

The mean age at OFG onset was 11.1 ± 3.8 years (range: 2.0–18 years). Although not all reports detailed the sex of the patients, OFG appeared to be significantly more prevalent in boys than in girls ($P < 0.001$, Table 1), with a male to female ratio of 2:1. The disease was reported more commonly in children of Caucasian origin.

The primary clinical feature of children with OFG was lip swelling (93.3%), with involvement of either one or both lips (Table 2). About half of the children presented some intraoral manifestations, such as ulcers, gingival hyperemia or hypertrophy, oral cobble-stoning lesions, or tongue abnormalities. Both angular cheilitis and perioral swelling were each present in about 20% of children. Gastrointestinal signs or symptoms (perianal disease, and/or abdominal pain, diarrhea, or intestinal bleeding) were present in 26.0% of the cases at time of OFG diagnosis.

The diagnosis of OFG was made more often by a team comprising different specialists (65.3%), rather than by one single type of physician (24.7%, $P < 0.001$, Table 3). Stomatologists and dentists were the specialists who were more frequently involved in the diagnosis of OFG (64.7%), followed by gastroenterologists (49.7%), while dermatologists and pediatricians were involved in the diagnosis in only 22.0% and 18.5% of cases, respectively. A consistent delay (months to years) in reaching the final diagnosis of OFG was frequently reported, with a single patient reporting up to 5 years delay^[18,42,52].

Differential diagnosis of Crohn's disease was considered in 79.2% of children, while sarcoidosis and tuberculosis were investigated in 20.8% and 14.4% of cases, respectively. Crohn's disease was diagnosed in 70/173 (40.4%) children with OFG, either at time of presentation of OFG, or during the following months or years (mean time: 13.1 ± 11.6 mo, range: 3–36 mo). In contrast, only three children (1.7%) were diagnosed with

tuberculosis^[33-35], two (1.1%) with sarcoidosis^[16], and 19 (10.9%) with allergy/atopy.

Overall, 21/173 (12.1%) of the children with OFG had perianal disease, while 11/173(6.4%) had a family history of Crohn's disease. Both perianal disease and a family history of inflammatory bowel disease were significantly associated with an increased risk of Crohn's disease in children with OFG (RR = 3.10, 95%CI: 2.46–3.90; RR = 2.74, 95%CI: 2.24–3.36, $P < 0.0001$ for both, Table 4).

There was heterogeneity in the reported incidence of Crohn's disease and of perianal disease among different case series, with those reported by gastroenterologists^[7,11], describing a significantly higher incidence of Crohn's disease than other series. In Campbell *et al*^[7], the largest OFG case series available including both adults and children (207 patients, of which 22% were children), the incidence of Crohn's disease was similar in children and adults with OFG, but in children the occurrence of OFG anticipated the onset of Crohn's disease significantly more often than in adults (84% *vs* 27%, $P = 0.0003$)^[7]. Ulcers and raised C-reactive protein were more frequent in patients with OFG and Crohn's disease than in those with OFG alone (respectively 49% *vs* 15%, $P = 0.001$ and 73% *vs* 49%, $P = 0.01$)^[7]. Cases with intraoral involvement, perianal disease and intestinal Crohn's disease were more likely to occur in those with childhood onset of OFG compared to those with adult onset (44% *vs* 24%, $P = 0.09$)^[7].

When Crohn's disease was diagnosed in children with OFG, oral and perioral lesions were not considered a metastatic manifestation of Crohn's disease, but an expression of the disease in the digestive tract.

Although the duration of follow-up was short in most reports, overall, 26.4% and 17.6% of children received two and three or more treatment attempts, respectively (Table 5). A combination of two or more drugs in the same treatment attempt was reported in 53.7% of children. Steroids were prescribed in 70.8% of children. Other immunosuppressive or immunomodulatory drugs were administered to 42.7% of children, and among these, azathioprine/6-mercaptopurine (6MP; 12.3%), thalidomide (10.1%) and infliximab (9.1%) were the most frequently prescribed. Eight (9.1%) children underwent surgery.

DISCUSSION

This review of the pediatric literature highlights the fact that OFG is a disease that can occur during childhood and adolescence. The exact prevalence of the disease in children is unknown, and cannot be derived from this review. Reports from specialized centers suggest that the real prevalence of the disease may be higher than what has been reported so far in the literature^[7]. Results from the present review also suggest that OFG in children is still not a well-known disease among physicians, and that there is uncertainty in respects to its diagnosis, with possible diagnostic delay.

This review highlights some important findings regarding Crohn's disease and OFG. First, Crohn's disease was diagnosed in 40.2% of children with OFG. This rate could be underestimated due to several factors: (1) Crohn's disease was not systematically assessed in all children with OFG; (2) on average, children were followed up for a short time, while this review highlights that gastrointestinal signs and symptoms may appear at a later stage (on average, 13 mo later); (3) Crohn's disease may be subclinical or silent, as observed in reports in adults, showing that a considerable percentage of patients with OFG without intestinal symptoms were diagnosed with Crohn's disease after ileoscopy or radiolabeled white cell screening^[58]; (4) patients with OFG were treated with steroids or other immunosuppressive drugs that could have silenced the intestinal symptoms of Crohn's disease; (5) publication bias may have affected the characteristics of reported cases; and (6) there is some confusion between the diagnosis of OFG and oral Crohn's disease^[59], and this may have affected the number of cases reported as OFG. Although some of the above-mentioned factors may have affected the prevalence of Crohn's disease in OFG by overestimating it, most factors may have led to an underestimation of the actual prevalence of Crohn's disease in OFG.

Second, 6.4% of children with OFG also presented a family history of inflammatory bowel disease. Such a percentage is much closer to what is reported in the population with Crohn's disease, than in those not affected by inflammatory bowel disease. Perianal disease, which is already a recognized subset of Crohn's disease, was detected in 12.1% of children with OFG overall. Intraoral lesions and perianal disease often occur together in Crohn's disease^[60], and cohort studies have showed that both manifestations are important predictors of Crohn's disease severity^[59,60].

Third, this review highlights other similarities between Crohn's disease and OFG:

both OFG and Crohn's disease^[58-60] are more prevalent in boys; both diseases have a long-term course; and treatments used for OFG resemble those used for Crohn's disease. Even the list of other diseases diagnosed in association with OFG (*i.e.*, erythema nodosum, and alopecia), although the number of cases was limited, resembles the list of immunological diseases usually associated with Crohn's disease.

All the above findings suggest that OFG and Crohn's disease may be two variants, if not just two different localizations, of the same chronic inflammatory disease. Other authors have proposed this hypothesis, based on the high (20%–50%) reported prevalence of Crohn's disease in adults with OFG^[5,6].

To the best of our knowledge no systematic review of adult cases of OFG has been carried out so far, and cases reported in adults suffer from the same risk of bias as cases reported in children (*e.g.*, short follow-up time). More studies in an adequate sample of patients with OFG (both children and adults) with a systematic evaluation for Crohn's disease and long follow-up time are needed to explore further the hypothesis that OFG is a subtype of Crohn's disease or even one of its manifestations.

So far, based on existing literature, Crohn's disease should be considered in the differential diagnosis of every child with signs of OFG; in particular, if other signs of systemic, gastrointestinal or perianal involvement are present. If Crohn's disease is not diagnosed at the time of OFG presentation, patients with OFG should be closely followed up for any sign of intestinal Crohn's disease, including perianal disease.

If OFG and Crohn's disease are two different clinical entities, more precise diagnostic criteria should be developed to differentiate between the two diseases.

In conclusion, OFG has been considered a different entity from Crohn's disease due to its presentation (lip and buccal involvement) and to the absence of systemic signs and symptoms^[1-5]. The findings of our systematic review on children with OFG suggest that OFG may be a subtype of Crohn's disease. More studies with a systematic evaluation of patients and with adequate follow-up are needed to confirm this hypothesis. Based on the existing evidence, Crohn's disease should be considered in the differential diagnosis of children with unexplained OFG. These children should be also followed up in the long term, because intestinal Crohn's disease may develop after several years.

ACKNOWLEDGMENTS

We would like to thank Genevieve Becker, for having revised the language of the manuscript.

REFERENCES

- 1 **Grave B**, McCullough M, Wiesenfeld D. Orofacial granulomatosis--a 20-year review. *Oral Dis* 2009; 15: 46-51 [PMID: 19076470 DOI: 10.1111/j.1601-0825.2008.01500.x]
- 2 **Tilakaratne WM**, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. *J Oral Pathol Med* 2008; **37**: 191-195 [PMID: 18321344 DOI: 10.1111/j.1600-0714.2007.00591.x]
- 3 **Al Johani K**, Moles DR, Hodgson T, Porter SR, Fedele S. Onset and progression of clinical manifestations of orofacial granulomatosis. *Oral Dis* 2009; **15**: 214-219 [PMID: 19222765 DOI: 10.1111/j.1601-0825.2009.01512.x]
- 4 **Al Johani KA**, Moles DR, Hodgson TA, Porter SR, Fedele S. Orofacial granulomatosis: clinical features and long-term outcome of therapy. *J Am Acad Dermatol* 2010; **62**: 611-620 [PMID: 20137827 DOI: 10.1016/j.jaad.2009.03.051]
- 5 **Sanderson J**, Nunes C, Escudier M, Barnard K, Shirlaw P, Odell E, Chinyama C, Challacombe S. Oro-facial granulomatosis: Crohn's disease or a new inflammatory bowel disease? *Inflamm Bowel Dis* 2005; **11**: 840-846 [PMID: 16116319 DOI: 10.1097/01.mib.0000178261.88356.67]
- 6 Prisma statement, available at <http://www.prisma-statement.org/> (accessed on 10th September 2013)
- 7 **Campbell H**, Escudier M, Patel P, Nunes C, Elliott TR, Barnard K, Shirlaw P, Poate T, Cook R, Milligan P, Brostoff J, Mentzer A, Lomer MC, Challacombe SJ, Sanderson JD. Distinguishing orofacial granulomatosis from crohn's disease: two separate disease entities? *Inflamm Bowel Dis* 2011; **17**: 2109-2115 [PMID: 21910172 DOI: 10.1002/ibd.21599]
- 8 **Saalman R**, Mattsson U, Jontell M. Orofacial granulomatosis in childhood-a clinical entity that may indicate Crohn's disease as well as food allergy. *Acta Paediatr* 2009; **98**: 1162-1167 [PMID: 19397547 DOI: 10.1111/j.1651-2227.2009.01295.x]
- 9 **Tuxen AJ**, Orchard D. Childhood and adolescent orofacial granulomatosis is strongly

- associated with Crohn's disease and responds to intralesional corticosteroids. *Australas J Dermatol* 2010; **51**: 124-127 [PMID: 20546219 DOI: 10.1111/j.1440-0960.2010.00627.x]
- 10 **Kolho KL**, Heiskanen K, Verkasalo M, Pitkäranta A. Orofacial granulomatosis in children--a challenge for diagnosis and treatment. *Int J Pediatr Otorhinolaryngol* 2011; **75**: 864-867 [PMID: 21458863 DOI: 10.1016/j.ijporl.2011.03.003]
- 11 **Khoury JM**, Bohane TD, Day AS. Is orofacial granulomatosis in children a feature of Crohn's disease? *Acta Paediatr* 2005; **94**: 501-504 [PMID: 16092468 DOI: 10.1111/j.1651-2227.2005.tb01925.x]
- 12 **Sainsbury CP**, Dodge JA, Walker DM, Aldred MJ. Orofacial granulomatosis in childhood. *Br Dent J* 1987; **163**: 154-157 [PMID: 3478055 DOI: 10.1038/sj.bdj.4806225]
- 13 **Hegarty A**, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003; **95**: 576-585 [PMID: 12738949 DOI: 10.1067/moe.2002.113]
- 14 **Clayden AM**, Bleys CM, Jones SF, Savage NW, Aldred MJ. Orofacial granulomatosis: a diagnostic problem for the unwary and a management dilemma. Case reports. *Aust Dent J* 1997; **42**: 228-232 [PMID: 9316309 DOI: 10.1111/j.1834-7819.1997.tb00126.x]
- 15 **Ahmad I**, Owens D. Granulomatous cheilitis and Crohn's disease. *Can J Gastroenterol* 2001; **15**: 273-275 [PMID: 11331931]
- 16 **Bourgeois-Droin C**, Havard S, Granier F, Vesse M, Salomon JL, Furioli J, Grossin M. Granulomatous cheilitis in two children with sarcoidosis. *J Am Acad Dermatol* 1993; **29**: 822-824 [PMID: 8408818 DOI: 10.1016/0190-9622(93)70246-P]
- 17 **El-Hakim M**, Chauvin P. Orofacial granulomatosis presenting as persistent lip swelling: review of 6 new cases. *J Oral Maxillofac Surg* 2004; **62**: 1114-1117 [PMID: 15346363 DOI: 10.1016/j.joms.2003.11.013]
- 18 **Lynde CB**, Bruce AJ, Orvidas LJ, Rogers RS, Depry JL. Cheilitis granulomatosa treated with intralesional corticosteroids and anti-inflammatory agents. *J Am Acad Dermatol* 2011; **65**: e101-e102 [PMID: 21839300 DOI: 10.1016/j.jaad.2011.04.027]
- 19 **Smith VM**, Murphy R. Orofacial granulomatosis: three case reports illustrating the spectrum of disease and overlap with Crohn's disease. *Clin Exp Dermatol* 2013; **38**: 33-35 [PMID: 22548302 DOI: 10.1111/j.1365-2230.2012.04377.x]

- 20 **Galbraith SS**, Drolet BA, Kugathasan S, Paller AS, Esterly NB. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. *Pediatrics* 2005; **116**: e439-e444 [PMID: 16099852 DOI: 10.1542/peds.2004-2281]
- 21 **Morton ME**, Ead RD. Granulomatous cheilitis. A report of three cases. *Br Dent J* 1984; **156**: 247-249 [PMID: 6584158 DOI: 10.1038/sj.bdj.4805330]
- 22 **Sakuntabhai A**, MacLeod RI, Lawrence CM. Intralesional steroid injection after nerve block anesthesia in the treatment of orofacial granulomatosis. *Arch Dermatol* 1993; **129**: 477-480 [PMID: 8466220 DOI: 10.1001/archderm.1993.01680250089013]
- 23 **Sussman GL**, Yang WH, Steinberg S. Melkersson-Rosenthal syndrome: clinical, pathologic, and therapeutic considerations. *Ann Allergy* 1992; **69**: 187-194 [PMID: 1524274]
- 24 **Kugathasan S**, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. *J Pediatr Gastroenterol Nutr* 2003; **37**: 150-154 [PMID: 12883301 DOI: 10.1097/00005176-200308000-00013]
- 25 **Camacho-Alonso F**, Bermejo-Fenoll A, López-Jornet P. Miescher's cheilitis granulomatosa. A presentation of five cases. *Med Oral Patol Oral Cir Bucal* 2004; **9**: 427-49; 427-49; [PMID: 15580120]
- 26 **Halevy S**, Shalom G, Trattner A, Bodner L. Melkersson-Rosenthal syndrome: a possible association with psoriasis. *J Am Acad Dermatol* 2012; **67**: 795-796 [PMID: 22980256 DOI: 10.1016/j.jaad.2012.04.022]
- 27 **Kruse-Lösler B**, Presser D, Metze D, Joos U. Surgical treatment of persistent macrocheilia in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. *Arch Dermatol* 2005; **141**: 1085-1091 [PMID: 16172304 DOI: 10.1001/archderm.141.9.1085]
- 28 **Ellitsgaard N**, Andersson AP, Worsaae N, Medgyesi S. Long-term results after surgical reduction cheiloplasty in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. *Ann Plast Surg* 1993; **31**: 413-420 [PMID: 8285526]
- 29 **Vijayalakshmi AM**, Jayavardhana A. Persistent swelling of lip. *Indian Pediatr* 2009; **46**: 907-908 [PMID: 19887698]
- 30 **Oliver DW**, Scott MJ. Lip reduction cheiloplasty for Miescher's granulomatous

- macrocheilitis (Cheilitis granulomatosa) in childhood. *Clin Exp Dermatol* 2002; **27**: 129-131 [PMID: 11952705 DOI: 10.1046/j.1365-2230.2002.00974.x]
- 31 **Olivier V**, Lacour JP, Castanet J, Perrin C, Ortonne JP. [Cheilitis granulomatosa in a child]. *Arch Pediatr* 2000; **7**: 274-277 [PMID: 10761605 DOI: 10.1016/S0929-693X(00)88745-X]
- 32 **Bourrat E**, Faure C, Vignon-Pennamen MD, Rybojad M, Morel P, Navarro J. [Anitis, vulvar edema and macrocheilitis disclosing Crohn disease in a child: value of metronidazole]. *Ann Dermatol Venereol* 1997; **124**: 626-628 [PMID: 9739927]
- 33 **Ramesh V**. Orofacial Granulomatosis due to Tuberculosis. *Pediatr Dermatol* 2009; **26**: 108-109 [PMID: 19250428 DOI: 10.1111/j.1525-1470.2008.00840.x]
- 34 **Bhattacharya M**, Rajeshwari K, Sardana K, Gupta P. Granulomatous cheilitis secondary to tuberculosis in a child. *J Postgrad Med* ; **55**: 190-192 [PMID: 19884744]
- 35 **Kruschinski C**, Welkoborsky HJ. Tuberculosis of the larynx associated with orofacial granulomatosis in childhood. *Otolaryngol Head Neck Surg* 2005; **132**: 967-969 [PMID: 15944576 DOI: 10.1016/j.otohns.2004.09.116]
- 36 **Dodi I**, Verri R, Brevi B, Bonetti L, Balestrier A, Saracino A, Akamin R, Izzi GC, Vanelli M, Sesenna E. A monosymptomatic Melkersson-Rosenthal syndrome in an 8-year old boy. *Acta Biomed* 2006; **77**: 20-23 [PMID: 16856704]
- 37 **Dummer W**, Lurz C, Jeschke R, Meissner N, Rose C, Bröcker EB. Granulomatous cheilitis and Crohn's disease in a 3-year-old boy. *Pediatr Dermatol* 1999; **16**: 39-42 [PMID: 10027998 DOI: 10.1046/j.1525-1470.1999.99012.x]
- 38 **Bogenrieder T**, Rogler G, Vogt T, Landthaler M, Stolz W. Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. *Dermatology* 2003; **206**: 273-278 [PMID: 12673090 DOI: 10.1159/000068900]
- 39 **Nabatian AS**, Shah KN, Iofel E, Rosenberg S, Javidian P, Pappert A, Milgraum SS. Asymptomatic granulomatous vulvitis and granulomatous cheilitis in childhood: the need for Crohn disease workup. *J Pediatr Gastroenterol Nutr* 2011; **53**: 100-101 [PMID: 21694543 DOI: 10.1097/MPG.0b013e31820bcff9]
- 40 **Rana AP**. Orofacial granulomatosis: A case report with review of literature. *J Indian Soc Periodontol* 2012; **16**: 469-474 [PMID: 23162350 DOI: 10.4103/0972-124X.100934]

- 41 **Freeman GL**. Complement abnormality in Melkersson-Rosenthal. *Allergy* 2004; **59**: 362 [PMID: 14982525 DOI: 10.1046/j.1398-9995.2003.00187.x]
- 42 **Somech R**, Harel A, Rotshtein MS, Brazowski E, Reif S. Granulomatosis cheilitis and Crohn disease. *J Pediatr Gastroenterol Nutr* 2001; **32**: 339-341 [PMID: 11345191 DOI: 10.1097/00005176-200103000-00024]
- 43 **Mignogna MD**, Fedele S, Lo Russo L, Lo Muzio L. The multiform and variable patterns of onset of orofacial granulomatosis. *J Oral Pathol Med* 2003; **32**: 200-205 [PMID: 12653858 DOI: 10.1034/j.1600-0714.2003.00106.x]
- 44 **Kleine R**, Bröhl L, Amon U. [Treatment of granulomatous cheilitis with fumaric acid esters in a young woman]. *Hautarzt* 2011; **62**: 940-942 [PMID: 21523519 DOI: 10.1007/s00105-011-2174-1]
- 45 **Ishiguro E**, Hatamochi A, Hamasaki Y, Ishikawa S, Yamazaki S. Successful treatment of granulomatous cheilitis with roxithromycin. *J Dermatol* 2008; **35**: 598-600 [PMID: 18837707 DOI: 10.1111/j.1346-8138.2008.00530.x]
- 46 **van der Waal RI**, Schulten EA, van der Meij EH, van de Scheur MR, Starink TM, van der Waal I. Cheilitis granulomatosa: overview of 13 patients with long-term follow-up--results of management. *Int J Dermatol* 2002; **41**: 225-229 [PMID: 12066767 DOI: 10.1046/j.1365-4362.2002.01466.x]
- 47 **Pryce DW**, King CM. Orofacial granulomatosis associated with delayed hypersensitivity to cobalt. *Clin Exp Dermatol* 1990; **15**: 384-386 [PMID: 2225546 DOI: 10.1111/j.1365-2230.1990.tb02123.x]
- 48 **Macaigne G**, Harnois F, Boivin JF, Dikov D, Ridoux G, Cheaib S, Chayette C. Crohn's disease revealed by a cheilitis granulomatosa with favorable evolution by perfusions of infliximab: report of a case and review of the literature. *Clin Res Hepatol Gastroenterol* 2011; **35**: 147-149 [PMID: 21809492 DOI: 10.1016/j.clinre.2010.10.001]
- 49 **Ridder GJ**, Fradis M, Löhle E. Cheilitis granulomatosa Miescher: treatment with clofazimine and review of the literature. *Ann Otol Rhinol Laryngol* 2001; **110**: 964-967 [PMID: 11642431]
- 50 **Diamond T**, Patterson PG, Emerson TG. Oral Crohn's disease: the distinction from the Melkersson-Rosenthal syndrome. *Ulster Med J* 1990; **59**: 223-24, 186 [PMID: 2278125]

- 51 **Gall Y**, Bureau B, Stalder JF, Litoux P. [Miescher's granulomatous macrocheilitis. Treatment with clofazimine]. *Ann Dermatol Venereol* 1989; **116**: 241-244 [PMID: 2742304]
- 52 **Wadlington WB**, Riley HD, Lowbeer L. The Melkersson-Rosenthal syndrome. *Pediatrics* 1984; **73**: 502-506 [PMID: 6709429]
- 53 **Henry CH**. Orofacial granulomatosis: report of a case with decreased CD4/CD8 ratio. *J Oral Maxillofac Surg* 1994; **52**: 317-322 [PMID: 8308635]
- 54 **William T**, Marsch WC, Schmidt F, Kreft B. Early oral presentation of Crohn's disease. *J Dtsch Dermatol Ges* 2007; **5**: 678-679 [PMID: 17659041]
- 55 **Rajah K**, Oliver MR, McLeod L, Orchard D, Leal M. Unusual manifestations of a common gastrointestinal disorder. *J Paediatr Child Health* 2014; **50**: 158-160 [PMID: 23662656 DOI: 10.1111/jpc.12220]
- 56 **Burke KR**, Green BP. An 11-year-old male with a swollen lip. *Clin Pediatr (Phila)* 2013; **52**: 678-680 [PMID: 23661791 DOI: 10.1177/0009922813488655]
- 57 **Howell JL**, Bussell RM, Hegarty AM, Zaitoun H. Service evaluation of patients with orofacial granulomatosis and patients with oral Crohn's disease attending a paediatric oral medicine clinic. *Eur Arch Paediatr Dent* 2012; **13**: 191-196 [PMID: 22883358]
- 58 **Rowland M**, Fleming P, Bourke B. Looking in the mouth for Crohn's disease. *Inflamm Bowel Dis* 2010; **16**: 332-337 [PMID: 19705418 DOI: 10.1002/ibd.20983]
- 59 **Wolters FL**, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Langholz E, Bodini P, O'Morain C, Katsanos K, Tsianos E, Vermeire S, Van Zeijl G, Limonard C, Hoie O, Vatn M, Moum B, Stockbrügger RW. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. *Scand J Gastroenterol Suppl* 2006; **243**: 46-54 [PMID: 16782622]
- 60 **Tarrant KM**, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. *Am J Gastroenterol* 2008; **103**: 3082-3093 [PMID: 19086959 DOI: 10.1111/j.1572-0241.2008.02212.x]




Figure 1 Case 1, swelling of both lips and gingival lesions (A, B), Histological examination showing typical noncaseating granulomas (arrows) and inflammatory infiltrate (C, D).




Figure 2 Flow diagram of studies selection.

Table 1 Demographic characteristic of children with orofacial granulomatosis *n* (%)

Patient characteristics	Value (<i>n</i> = 173)	<i>P</i> value
Age, mean ± SD (range, yr)	11.1 ± 3.8 (2-18)	
Sex		
Male	69 (39.9)	< 0.001 ¹
Female	34 (19.6)	
unspecified	70 (40.5)	
Ethnic group		
Caucasian	19 (11.0)	< 0.001 ¹
African	3 (1.7)	
Indian	2 (1.2)	
unspecified	149 (86.1)	

¹Indicate similarities with Crohn's disease.

Table 2 Clinical manifestations in children diagnosed with orofacial granulomatosis *n* (%)

Clinical features	Value (<i>n</i> = 104) ²
<i>Lips</i>	
Present	104 (100)
Lip swelling	97 (93.3)
Only upper lip	27 (26.0)
Only lower lip	15 (14.4)
Both lips	26 (25.0)
Preset but unspecified	29 (27.9)
Angular cheilitis	22 (21.1)
<i>Oral manifestation¹</i>	
Present	50 (48.1)
Oral ulcerations	24 (23.1)
Gingival hyperemia/hypertrophy	22 (21.1)
Tongue abnormalities	8 (7.7)
Oral cobble-stoning lesions	8 (7.7)
<i>Facies</i>	
Perioral/cheek swelling	19 (18.3)
<i>Neck</i>	
Cervical lymphadenopathy ¹	6 (5.8)
Gastrointestinal	27 (26.0)
Present	21 (20.2)
Perianal disease ¹	7 (6.7)
Abdominal pain ¹	7 (6.7)

Diarrhea ¹	6 (5.8)
Intestinal bleeding ¹	
Nutritional status	5 (4.8)
Impaired growth ¹	1 (1.0)
Obesity	
Ocular	1 (1.0)
Conjunctivitis ¹	
Genitalia	2 (2.0)
Vulvar oedema ¹	1 (1.0)
Scrotal swelling ¹	

¹The asterisks indicate similarities with Crohn's disease; ²All cases with a detailed description of clinical signs and symptoms are reported in the table.

Table 3 Diagnostic process in children reported with orofacial granulomatosis *n* (%)

Characteristics	Value (<i>n</i> = 173)
Physicians involved in the diagnosis	
Stomatologist/ dentist/ maxillo surgeon	112 (64.7)
Gastroenterologist	86 (49.7)
Dermatologist	38 (22.0)
Pediatrician	32 (18.5)
Otorhinolaryngologist	13 (7.5)
Allergologist	4 (2.3)
Plastic surgeon	3 (1.7)
Internal Medicine	1 (0.6)
Composition of the team	
One single specialty	60 (34.7)
More than one specialty	113 (65.3)
Differential diagnosis considered at time of OFG presentation	
Crohn's disease	137 (79.2)
Sarcoidosis	36 (20.8)
Tuberculosis	25 (14.4)
Allergy	19 (11.0)
Infection	17 (9.8)
C1q esterase deficiency	10 (5.8)
Melkersson-Rosenthal syndrome	4 (2.3)
Autoimmunity	3 (1.7)
Vasculitis	1 (0.6)
Foreign body	1 (0.6)
Enteropathic acrodermatitis	1 (0.6)

Table 4 Concomitant diseases diagnosed in children with orofacial granulomatosis and associated characteristics *n* (%)

Disease	Value [<i>n</i> = 173]	RR (95%CI), <i>P</i>
Crohn's disease		
Total children	70 (40.4)	
At presentation	34 (19.6)	
During follow-up	36 (20.8)	
Time from OFG diagnosis to Crohn's diagnosis (mean ± SD, range)	13.1 ± 11.6 (3-36)	
Presence of perianal disease		
Total		
In children with Crohn's		
In children without Crohn's	21/173 (12.1)	3.10 (2.46-3.90), 0.0001
Familiarity for inflammatory bowel diseases	21/70 (30.0)	0.0001
Total	0/103 (0)	
In children with Crohn's		
In children without Crohn's		
Allergy /atopy	11/173 (6.4)	2.74 (2.24-3.36), 0.0001
Any allergy	11/70 (15.7)	0.0001
Asthma	0/103 (0)	
Atopy		
Rhinitis/rhinoconjunctivitis		
Eczema	19 (10.9)	
Hives	7 (4.0)	
Other diagnosis	6 (3.5)	
Tuberculosis	6 (3.5)	

Sarcoidosis	1 (0.6)
Other diseases	
Erythema nodosum	3 (1.7)
Insulin dependent diabetes	2 (1.1)
Celiac disease	10 (5.7)
Alopecia	3 (1.7)
Low CD4/CD8 ratio	1 (0.6)
Epilepsy	1 (0.6)
	1 (0.6)
	1 (0.6)
	1 (0.6)

Table 5 Treatments of children with orofacial granulomatosis *n* (%)

Treatment characteristics	Value (<i>n</i> = 104)¹
A treatment was prescribed ²	
Yes	89 (96.7)
No	3 (3.2)
(unspecified)	12 (11.5)
Number of treatment attempts reported ²	
One	38 (55.8)
Two	18 (26.4)
Three or more	12 (17.6)
(unspecified)	21 (23.5)
More than one drug in the same treatment attempt ²	
Yes	36 (53.7)
No	31 (46.2)
(unspecified)	22 (24.7)
Type of treatments prescribed ²	
Antibiotics	26 (29.2)
Anti-histaminic	10 (11.2)
Steroids- total	63 (70.8)
Topical	27 (30.3)
Intralesional	24 (27.0)
Oral	39 (43.8)
Other immunosuppressive- total	38 (42.7)

Azathioprine/6MP	11 (12.3)
Thalidomide	9 (10.1)
Infliximab	8 (9.0)
Dapsone	4 (4.5)
Tacrolimus (topic)	4 (4.5)
Methotrexate	3 (3.4)
Tacrolimus (systemic)	3 (3.4)
Hydroxychloroquine,/chloroquine	2 (2.2)
Colchicine	2 (2.2)
Other treatments	
5ASA	13 (14.6)
Chlorhexidine (topic)	4 (4.5)
Enteral nutrition	2 (2.2)
Fumaric acid esterase	1 (1.1)
Surgery	8 (9.0)

¹All cases that provided a detail description of clinical signs are reported in the table;

²Percentages are calculated on the number of children for which the treatment was specified. 5-AZA: 5-aminosalicylic acid.